We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 06, 2021

Prediction Model of Primary Resistance to Palbociclib + Letrozole as 1L Treatment for HR+/HER2− Advanced Breast Cancer

Frontiers in Oncology


Additional Info

Frontiers in Oncology
Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer?
Front Oncol 2021 Dec 01;11(xx)759150, JY Kim, JM Oh, YH Park, JS Ahn, YH Im

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading